In the journey to outperform the market, investors delve into the art of stock selection. Choosing the right stocks can be a powerful driver for wealth accumulation.
After finishing at $3.49 in the prior trading day, Oncology Institute Inc (NASDAQ: TOI) closed at $3.46, down -0.86%. In other words, the price has decreased by -$0.86 from its previous closing price. On the day, 0.95 million shares were traded. TOI stock price reached its highest trading level at $3.55 during the session, while it also had its lowest trading level at $3.41.
Ratios:
Our goal is to gain a better understanding of TOI by taking a closer look at its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 1.37 and its Current Ratio is at 1.62.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for this company, Noble Capital Markets on July 23, 2025, initiated with a Outperform rating and assigned the stock a target price of $8. On July 16, 2025, B. Riley Securities started tracking the stock assigning a Buy rating and target price of $6.
On May 15, 2025, BTIG Research started tracking the stock assigning a Buy rating and target price of $7.BTIG Research initiated its Buy rating on May 15, 2025, with a $7 target price.
Insider Transactions:
The insider trade also gives investors a glimpse into the future direction of stock prices, which can be beneficial to investors. A recent insider transaction in this stock occurred on Aug 19 ’25 when Hively Brad sold 20,221 shares for $4.06 per share. The transaction valued at 82,097 led to the insider holds 622,980 shares of the business.
M33 Growth I L.P. sold 673,676 shares of TOI for $2,054,712 on Jun 05 ’25. The Director now owns 13,950,557 shares after completing the transaction at $3.05 per share. On Jun 05 ’25, another insider, M33 Growth I L.P., who serves as the Director of the company, sold 76,324 shares for $3.05 each. As a result, the insider received 232,788 and left with 1,272,724 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, TOI now has a Market Capitalization of 323526624 and an Enterprise Value of 396317984. For the stock, the TTM Price-to-Sale (P/S) ratio is 0.76. Its current Enterprise Value per Revenue stands at 0.934 whereas that against EBITDA is -9.899.
Stock Price History:
The Beta on a monthly basis for TOI is 0.13, which has changed by 8.057591 over the last 52 weeks, in comparison to a change of 0.1590569 over the same period for the S&P500. Over the past 52 weeks, TOI has reached a high of $4.50, while it has fallen to a 52-week low of $0.13. The 50-Day Moving Average of the stock is 5.53%, while the 200-Day Moving Average is calculated to be 96.09%.
Shares Statistics:
The stock has traded on average 2.07M shares per day over the past 3-months and 1802220 shares per day over the last 10 days, according to various share statistics. A total of 93.28M shares are outstanding, with a floating share count of 46.20M. Insiders hold about 50.60% of the company’s shares, while institutions hold 27.86% stake in the company. Shares short for TOI as of 1755216000 were 6248161 with a Short Ratio of 3.03, compared to 1752537600 on 7145146. Therefore, it implies a Short% of Shares Outstanding of 6248161 and a Short% of Float of 8.1499994.
Earnings Estimates
At present, 3 analysts are actively evaluating the performance of Oncology Institute Inc (TOI) in the stock market.The consensus estimate for the next quarter is -$0.1, with high estimates of -$0.06 and low estimates of -$0.14.
Analysts are recommending an EPS of between -$0.49 and -$0.6 for the fiscal current year, implying an average EPS of -$0.55. EPS for the following year is -$0.21, with 2.0 analysts recommending between -$0.14 and -$0.28.
Revenue Estimates
For the next quarter, 3 analysts are estimating revenue of $126.77M. There is a high estimate of $128.1M for the next quarter, whereas the lowest estimate is $124.5M.
Based on 3 analysts’ estimates, the company’s revenue will be $564.43M in the next fiscal year. The high estimate is $582.4M and the low estimate is $550M.
